arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


|
 

Treatment of Hepatitis C Infection: Interpreting The Latest Data From AASLD (The Liver Meeting) 2013 (Monograph)


Presented by the Johns Hopkins University School of Medicine.

This educational activity is supported by an educational grant from AbbVie, Inc.

GOAL

The goal of this activity is to provide clinicians who treat and manage patients with hepatitis C virus (HCV) with the most up-to-date clinical information as presented at the American Association for the Study of Liver Disease’s Liver Meeting 2013 to improve understanding and communication with their patients and families and improve outcomes.

INTENDED AUDIENCE

This activity is designed for gastroenterologists, hepatologists, infectious disease specialists, primary care providers, nurse practitioners, physician assistants, and nurses who manage patients with HCV. No prerequisites required.

LEARNING OBJECTIVES

After completing this activity, the participant should be able to:

  • Evaluate recent updates to the current standard of care for HCV, including new guidelines and recent clinical trial results.
  • Identify emerging treatment options and their potential role in the treatment and cure of HCV recent data on emerging therapeutic options in the treatment and cure of HCV.
  • Assess available data on the cost-effectiveness of various HCV therapies.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category I Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The estimated time to complete this educational activity: 1.5 hours.

Release date: July 2, 2014. Expiration date: July 2, 2015.

PARTICIPATING FACULTY
Mark Sulkowski, MD (Course Director/Faculty)
Professor of Medicine
Medical Director of the Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, MD
HOW TO CLAIM CREDIT
Please complete a brief pre-assessment before continuing with the monograph. After reading this monograph, participants may receive credit by completing the CME test and evaluation online, and receiving a score of 70% or higher.

Faculty
Full Disclosure Policy Affecting CME Activities:
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Participating Faculty Disclosures
Dr Sulkowski reports serving as a principal investigator and a consultant for Abbott, BIPI, Bristol-Myers Squibb Company, Gilead, Janssen, Merck & Co, Inc, Roche, and Vertex Pharmaceuticals Incorporated; and reports serving as a consultant for Novartis Corporation and Pfizer Inc.

Planner Disclosures
Planning Committee:Mark Sulkowski, MD, Kate Biles, and Nancy Reau, MD.

Dr Sulkowski reports serving as a principal investigator and a consultant for Abbott, BIPI, Bristol-Myers Squibb Company, Gilead, Janssen, Merck & Co, Inc, Roche, and Vertex Pharmaceuticals ncorporated; and reports serving as a consultant for Novartis Corporation and Pfizer Inc.

Dr Reau reports serving as a principal investigator for AbbVie Inc, Boehringer Ingelheim, Genentech, Inc, Gilead, Janssen, and Vertex Pharmaceuticals Incorporated; and reports serving as a consultant for AbbVie Inc, Facilitate, Gilead, Idenix Pharmaceuticals, Inc, and Janssen.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
No faculty member has indicated that their presentation will include information on off-label products.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

Confidentiality Disclaimer for CME Activity Participant

I certify that I am participating in a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office (410) 955-2959 or e-mail cmenet@jhmi.edu.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (Updated 4/09)

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY

Instructions
The following activity consists of 3 sections: an unaccredited pre-test, a monograph, and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit.


Pre-Test

OVERVIEW
Treatment of Hepatitis C Infection: Interpreting the Latest Data from AASLD

PROCEEDINGS
The New Standard of Care in HCV Treatment

Mark Sulkowski, MD

The Next Wave of HCV Care: All-Oral Treatment Strategies
Mark Sulkowski, MD

Cost Effectiveness of HCV Therapy
Mark Sulkowski, MD

Post-Test
procced to pretest




Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.